Bd announces fda emergency use authorization for combination covid-19, flu rapid antigen test

Franklin lakes, n.j., march 30, 2021 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced the u.s. food and drug administration (fda) granted emergency use authorization (eua) for a new, rapid antigen test that can detect sars-cov-2, influenza a and influenza b in a single test.
BDX Ratings Summary
BDX Quant Ranking